Compare AMPH & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPH | CTMX |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.8M | 977.1M |
| IPO Year | 2005 | 2015 |
| Metric | AMPH | CTMX |
|---|---|---|
| Price | $19.31 | $3.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $28.38 | $12.10 |
| AVG Volume (30 Days) | 371.8K | ★ 3.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $719,887,000.00 | $76,201,000.00 |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $4.64 | $7.61 |
| P/E Ratio | ★ $11.87 | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.03 | $1.72 |
| 52 Week High | $31.26 | $8.21 |
| Indicator | AMPH | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 36.58 | 36.51 |
| Support Level | $18.92 | $3.83 |
| Resistance Level | $20.08 | $3.91 |
| Average True Range (ATR) | 0.80 | 0.25 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 14.80 | 3.96 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.